Kawazoe Akihito, Yamaguchi Kensei, Hamaguchi Tetsuya, Narita Yukiya, Boku Shogen, Oshima Takashi, Hara Hiroki, Hamamoto Yasuo, Ishido Kenji, Esaki Taito, Hosaka Hisashi, Yasui Hirofumi, Koeda Keisuke, Nishina Tomohiro, Tsuji Yasushi, Fukagawa Takeo, Goto Masahiro, Oki Eiji, Sugimoto Naotoshi, Matsuoka Hiroshi, Yokoyama Fumiharu, Yoshida Tomoko, Yoshida Kazuo, Oshima Yoshiaki, Iwasa Satoru. ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer(タイトル和訳中) Cancer Science. 2025.09; 116 (9): 2523-2536. ( ichushi )

ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. 2025.09; 116 (9): 2523-2536. ( PubMed, DOI )

So Eiichiro, Hayashi Hideyuki, Shimozaki Keitaro, Horie Sara, Kishimoto Shotaro, Chida Akihiko, Saito Yuki, Tsugaru Kai, Hirata Kenro, Tanishima Shigeki, Nishihara Hiroshi, Kanai Takanori, Hamamoto Yasuo. 進行膵癌における包括的ゲノムプロファイリングの臨床的有用性　実臨床データ解析からの洞察(Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis) International Journal of Clinical Oncology. 2025.04; 30 (4): 728-737. ( ichushi )

Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia. 2024.12; 28 (6): 568. ( PubMed, DOI )

The Effectiveness and Feasibility of Palliative Care via Video Telemedicine for Patients with Advanced Cancer: A Nonrandomized Prospective Clinical Trial Comparing Combination of Telemedicine and in-Person Care with in-Person Care Alone. 2024; 5 (1): 503-511. ( PubMed, DOI )

共生細菌とがん免疫応答 胃癌患者における腸内細菌由来代謝物Dアミノ酸の意義(Commensal bacteria and tumor immunity Significance of novel microbial metabolites, d-amino acids, in gastric cancer patients) 2023.09; 82回 1656. ( ichushi )

共生細菌とがん免疫応答 胃癌患者における腸内細菌由来代謝物Dアミノ酸の意義(Commensal bacteria and tumor immunity Significance of novel microbial metabolites, d-amino acids, in gastric cancer patients) 2023.09; 82回 1656. ( ichushi )

高齢者・フレイル食道癌患者に対する治療戦略 高齢切除可能胸部食道癌患者における高齢者機能評価の有用性の多施設前向き観察研究 2023.06; 77回 51. ( ichushi )

オンライン診療を用いた緩和ケアの有用性に関する検討 2022.10; 60回 O76-3. ( ichushi )

Keitaro Shimozaki, Kenro Hirata, Taro Sato, Maho Nakamura, Kyoko Kato, Hidekazu Hirano, Yosuke Kumekawa, Kaori Hino, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Takeshi Kawakami, Masato Komoda, Kengo Nagashima, Yasunori Sato, Kentaro Yamazaki, Shuichi Hironaka, Hiromasa Takaishi, Yasuo Hamamoto, Kei Muro. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study) Clinical Colorectal Cancer. 2022.08; In press. ( DOI )

Hamamoto Yasuo, Murakami Kentaro, Kato Ken, Kitagawa Yuko. 高齢食道扁平上皮癌患者の管理(Management of elderly patients with esophageal squamous cell cancer) Japanese Journal of Clinical Oncology. 2022.08; 52 (8): 808-816. ( ichushi )

Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. 2022.02; 6 e2100383. ( PubMed, DOI )

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. 2022.01; 25 (1): 207-217. ( PubMed, DOI )

Kang Yoon-Koo, Morita Satoshi, Satoh Taroh, Ryu Min-Hee, Chao Yee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Sameshima Hiroki, Chen Li-Tzong, Boku Narikazu. 治療既往のある進行胃ないし胃食道接合部癌患者に対する、ニボルマブ単独療法の利点の予測に関する検討　ATTRACTION-2試験の事後サブ解析(Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study) Gastric Cancer. 2022.01; 25 (1): 207-217. ( ichushi )

Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. 2021.10; 11 (1): 20003. ( PubMed, DOI )

Satoh Taroh, Kato Ken, Ura Takashi, Hamamoto Yasuo, Kojima Takashi, Tsushima Takahiro, Hironaka Shuichi, Hara Hiroki, Iwasa Satoru, Muro Kei, Yasui Hirofumi, Minashi Keiko, Yamaguchi Kensei, Ohtsu Atsushi, Doki Yuichiro, Matsumura Yasuhiro, Kitagawa Yuko. 食道扁平上皮癌の日本人患者に対するニボルマブ療法の5年間の経過観察(ATTRACTION-1/ONO-4538-07)(Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma(ATTRACTION-1/ONO-4538-07)) Esophagus. 2021.10; 18 (4): 835-843. ( ichushi )

Shimozaki K, Sukawa Y, Sato Y, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Kanai T. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data Future Oncology. 2021.07; 17 (20): 2593-2603. ( PubMed, DOI )

Boku N, Satoh T, Ryu M.H, Chao Y, Kato K, Chung H.C, Chen J.S, Muro K, Kang W.K, Yeh K.H, Yoshikawa T, Oh S.C, Bai L.Y, Tamura T, Lee K.W, Hamamoto Y, Kim J.G, Chin K, Oh D.Y, Minashi K, Cho J.Y, Tsuda M, Nishiyama T, Chen L.T, Kang Y.K. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Gastric Cancer. 2021.07; 24 (4): 946-958. ( PubMed, DOI )

Boku Narikazu, Satoh Taroh, Ryu Min-Hee, Chao Yee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Nishiyama Taihei, Chen Li-Tzong, Kang Yoon-Koo. 治療既往のある進行胃癌に対するニボルマブ(ATTRACTION-2)　3年目の報告およびニボルマブ投与での病勢進行後の経過(Nivolumab in previously treated advanced gastric cancer(ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab) Gastric Cancer. 2021.07; 24 (4): 946-958. ( ichushi )

Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya K.J.L, Tsugaru K, Shimozaki K, Hirata K, Fukuhara K, Fukuhara S, Mutaguchi M, Sujino T, Sukawa Y, Hamamoto Y, Naganuma M, Takaishi H, Shimoda M, Ogata H, Kanai T. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis Digestive Diseases and Sciences. 2021.06; 66 (6): 2129-2134. ( PubMed, DOI )

Shimozaki K, Hirata K, Horie S, Chida A, Tsugaru K, Hayashi Y, Kawasaki K, Miyanaga R, Hayashi H, Mizuno R, Funakoshi T, Hosoe N, Hamamoto Y, Kanai T. The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: A prospective observational study Diagnostics. 2021.03; 11 (3): ( PubMed, DOI )

Takeuchi M, Imamura C.K, Booka E, Takeuchi H, Mizukami T, Kawakami T, Funakoshi T, Wakuda K, Aoki Y, Hamamoto Y, Kitago M, Kawakubo H, Boku N, Tanigawara Y, Kitagawa Y. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application Cancer Science. 2021.02; 112 (2): 751-759. ( PubMed, DOI )

Takeuchi Masashi, Imamura Chiyo K., Booka Eisuke, Takeuchi Hiroya, Mizukami Takuro, Kawakami Takeshi, Funakoshi Taro, Wakuda Kazushige, Aoki Yu, Hamamoto Yasuo, Kitago Minoru, Kawakubo Hirofumi, Boku Narikazu, Tanigawara Yusuke, Kitagawa Yuko. 臨床応用のための腎機能に基づくS-1用量算出式の前方視的評価と改良(Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application) Cancer Science. 2021.02; 112 (2): 751-759. ( ichushi )

Katada Chikatoshi, Sugawara Mitsuhiro, Hara Hiroki, Fujii Hirofumi, Eguchi Nakajima Takako, Ando Takayuki, Kojima Takashi, Watanabe Akinori, Sakamoto Yasutoshi, Ishikawa Hideki, Hosokawa Ayumu, Hamamoto Yasuo, Muto Manabu, Tahara Makoto, Koizumi Wasaburo. 食道扁平上皮癌患者においてG-CSFを用いた好中球減少症の管理はドセタキセル、シスプラチン、5-フルオロウラシル化学療法の支持療法となる(A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma) Japanese Journal of Clinical Oncology. 2021.02; 51 (2): 199-204. ( ichushi )

Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC. 2021.01; 39 (3): ( DOI )

Takahashi Masanobu, Kato Ken, Okada Morihito, Chin Keisho, Kadowaki Shigenori, Hamamoto Yasuo, Doki Yuichiro, Kubota Yutaro, Kawakami Hisato, Ogata Takashi, Hara Hiroki, Muto Manabu, Nakashima Yuichiro, Ishihara Ryu, Tsuda Masahiro, Motoyama Satoru, Kodani Mamoru, Kitagawa Yuko. 日本人進行食道扁平上皮癌患者を対象としたニボルマブ投与と化学療法の比較　多施設無作為化非盲検第3相試験(ATTRACTION-3)のサブグループ解析(Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial(ATTRACTION-3)) Esophagus. 2021.01; 18 (1): 90-99. ( ichushi )

Satoh T, Kato K, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Matsumura Y, Kitagawa Y. Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) Esophagus. 2021; 18 (4): 835-843. ( PubMed, DOI )

Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim H.G, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping Cell. 2020.11; 183 (5): 1420-1435.e21. ( PubMed, DOI )

Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. 2020.10; ( PubMed, DOI )

Kayashima Atsuto, Sujino Tomohisa, Shimozaki Keitaro, Mutaguchi Makoto, Hirata Kenro, Sukawa Yasutaka, Takabayashi Kaoru, Hayashi Yuichiro, Hamamoto Yasuo, Hosoe Naoki, Naganuma Makoto, Ogata Haruhiko, Kanai Takanori. ニボルマブ開始後に増悪し特異な内視鏡的所見を呈した潰瘍性結腸炎の1症例(A case of ulcerative colitis exacerbated after starting nivolumab and followed a unique endoscopic feature) Gastroenterological Endoscopy. 2020.08; 62 (Suppl.1): 1202. ( ichushi )

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. 2020.06; 20 (1): 548. ( PubMed, DOI )

Chen L.T, Satoh T, Ryu M.H, Chao Y, Kato K, Chung H.C, Chen J.S, Muro K, Kang W.K, Yeh K.H, Yoshikawa T, Oh S.C, Bai L.Y, Tamura T, Lee K.W, Hamamoto Y, Kim J.G, Chin K, Oh D.Y, Minashi K, Cho J.Y, Tsuda M, Sameshima H, Kang Y.K, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Gastric Cancer. 2020.05; 23 (3): 510-519. ( PubMed, DOI )

Kato Ken, Doki Yuichiro, Ura Takashi, Hamamoto Yasuo, Kojima Takashi, Tsushima Takahiro, Hironaka Shuichi, Hara Hiroki, Kudo Toshihiro, Iwasa Satoru, Muro Kei, Yasui Hirofumi, Minashi Keiko, Yamaguchi Kensei, Ohtsu Atsushi, Kitagawa Yuko. 日本人食道癌患者に対するニボルマブ反応の長期有効性および同反応を予測する相関因子(Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer) Cancer Science. 2020.05; 111 (5): 1676-1684. ( ichushi )

Chen Li-Tzong, Satoh Taroh, Ryu Min-Hee, Chao Yee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Sameshima Hiroki, Kang Yoon-Koo, Boku Narikazu. 治療歴のある進行性胃癌または食道胃接合部癌を対象としたニボルマブの第III相試験(ATTRACTION-2)　2年間の最新データ(A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer(ATTRACTION-2): 2-year update data) Gastric Cancer. 2020.05; 23 (3): 510-519. ( ichushi )

Hamamoto Yasuo, Piao Yongzhe, Makiyama Akitaka. 進行性胃癌における逐次療法の実現　高齢者/腹水を有する患者の適切な管理の重要性(Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites) Gastric Cancer. 2020.05; 23 (3): 363-372. ( ichushi )

Suzuki T, Sukawa Y, Imamura C, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial) Clinical Colorectal Cancer. 2020.03; 19 (1): 13-21. ( PubMed, DOI )

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. 2020.02; 27 (2): 460-467. ( PubMed, DOI )

Kunimasa K, Hirotsu Y, Nakamura H, Tamiya M, Iijima Y, Ishida H, Hamamoto Y, Maniwa T, Kimura T, Nishino K, Goto T, Amemiya K, Mochizuki H, Oyama T, Nakatsuka SI, Kumagai T, Okami J, Higashiyama M, Imamura F, Omata M. Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model. Cancer genetics. 2020.02; 241 51-56. ( PubMed, DOI )

Satoh Taroh, Kang Yoon-Koo, Chao Yee, Ryu Min-Hee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Tanimoto Mitsunobu, Chen Li-Tzong, Boku Narikazu. ATTRACTION-2試験においてトラスツズマブを事前使用されていた患者を対象とした探索的サブグループ解析　進行性の胃癌/食道胃接合部癌の患者におけるニボルマブの有効性と安全性を調査するランダム化第III相臨床試験(Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer) Gastric Cancer. 2020.01; 23 (1): 143-153. ( ichushi )

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. 2020; 12 4585-4593. ( PubMed, DOI )

Yagasaki K, Takahashi H, Ouchi T, Yamagami J, Hamamoto Y, Amagai M, Komatsu H. Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study Journal of Patient-Reported Outcomes. 2019.12; 3 (1): 27. ( PubMed, DOI )

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. 2019.11; 20 (11): 1506-1517. ( PubMed, DOI )

新規臨床試験最新情報 食道がんに対するニボルマブの開発状況について 2019.10; 57回 SSY14-4. ( ichushi )

癌種横断的な免疫チェックポイント阻害剤の有効性におけるネットワークメタ解析 2019.10; 57回 P115-2. ( ichushi )

Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer 2019.07; 79 (13): ( DOI )

Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review. 2019.04; 20 (1): 120. ( PubMed, DOI )

Kato Ken, Satoh Taroh, Muro Kei, Yoshikawa Takaki, Tamura Takao, Hamamoto Yasuo, Chin Keisho, Minashi Keiko, Tsuda Masahiro, Yamaguchi Kensei, Machida Nozomu, Esaki Taito, Goto Masahiro, Komatsu Yoshito, Eguchi Nakajima Takako, Sugimoto Naotoshi, Yoshida Kazuhiro, Oki Eiji, Nishina Tomohiro, Tsuji Akihito, Fujii Hirofumi, Kunieda Kenji, Saitoh Soh, Omuro Yasushi, Azuma Mizutomo, Iwamoto Yasuo, Taku Keisei, Fushida Sachio, Chen Li-Tzong, Kang Yoon-Koo, Boku Narikazu. 2種類以上の化学療法レジメンに対して不応ないし不耐であった進行胃癌または胃食道接合部癌患者に対するニボルマブの第3相二重盲検プラセボ対照無作為化試験における日本人患者のサブ解析(ONO-4538-12,ATTRACTION-2)(A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2)) Gastric Cancer. 2019.03; 22 (2): 344-354. ( ichushi )

Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima T, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen L, Kang Y, Boku N. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) Gastric Cancer. 2019.03; 22 (2): 344-354. ( PubMed, DOI )

Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report. 2019.01; 10 (1): 113-117. ( PubMed, DOI )

Hashimoto Jun, Kato Ken, Ito Yoshinori, Kojima Takashi, Akimoto Tetsuo, Daiko Hiroyuki, Hamamoto Yasuo, Matsushita Hisayuki, Katano Susumu, Hara Hiroki, Tanaka Yoichi, Saito Yoshihiro, Nagashima Kengo, Igaki Hiroyasu. 臨床病期II/III期食道扁平上皮癌に対するシスプラチン+5-フルオロウラシルによる術前同時化学放射線療法と待機的リンパ節放射線照射に関する第II相実施可能性試験(Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma) International Journal of Clinical Oncology. 2019.01; 24 (1): 60-67. ( ichushi )

Satoh T, Kang Y, Chao Y, Ryu M, Kato K, Cheol Chung H, Chen J, Muro K, Ki Kang W, Yeh K, Yoshikawa T, Oh S, Bai L, Tamura T, Lee K, Hamamoto Y, Kim J, Chin K, Oh D, Minashi K, Cho J, Tsuda M, Tanimoto M, Chen L, Boku N. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer Gastric Cancer. 2019; 23 (1): 143-153. ( PubMed, DOI )

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. 2018.12; 17 (4): e719-e732. ( PubMed, DOI )

Minami Kazuhiro, Iwasaki Eisuke, Itoi Takao, Fukuhara Seiichiro, Horibe Masayasu, Seino Takashi, Kawasaki Shintaro, Katayama Tadashi, Takimoto Yoichi, Tamagawa Hiroki, Machida Yujiro, Hamamoto Yasuo, Ogata Haruhiko, Kanai Takanori. Successful EUS-guided antegrade stenting for malignant severe biliary obstruction combined with a newly developed plastic stent ENDOSCOPY INTERNATIONAL OPEN. 2018.11; 6 (11): E1336-E1339. ( PubMed, DOI )

Takeuchi M, Suda K, Hamamoto Y, Kato M, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Wada N, Kawakubo H, Takeuchi H, Yahagi N, Kitagawa Y. Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer Gastrointestinal Endoscopy. 2018.09; 88 (3): 456-465. ( PubMed, DOI )

Sawaki Akira, Yamada Yasuhide, Yamaguchi Kensei, Nishina Tomohiro, Doi Toshihiko, Satoh Taroh, Chin Keisho, Boku Narikazu, Omuro Yasushi, Komatsu Yoshito, Hamamoto Yasuo, Koizumi Wasaburo, Saji Shigehira, Shah Manish A., Van Cutsem Eric, Kang Yoon-Koo, Iwasaki Junko, Kuriki Hiroshi, Ohtsuka Wataru, Ohtsu Atsushi. 進行性胃癌における地域差　AVAGASTプラセボ群の探索的解析(Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm) Gastric Cancer. 2018.05; 21 (3): 429-438. ( ichushi )

Hamamoto Yasuo, Sakakibara Naoki, Nagashima Fumio, Kitagawa Yuko, Higashi Takahiro. 食道癌に対する治療選択　全国データベースの評価(Treatment selection for esophageal cancer: evaluation from a nationwide database) Esophagus. 2018.04; 15 (2): 109-114. ( ichushi )

Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis 2018.03; 1-10. ( DOI )

Yokota Tomoya, Yasuda Takushi, Kato Hiroyuki, Nozaki Isao, Sato Hiroshi, Miyata Yoshinori, Kuroki Yoshifumi, Kato Ken, Hamamoto Yasuo, Tsubosa Yasuhiro, Ogawa Hirofumi, Ito Yoshinori, Kitagawa Yuko. 局所切除不能胸部食道癌に対する医師間でのT分類臨床診断の一致(Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer) International Journal of Clinical Oncology. 2018.02; 23 (1): 73-80. ( ichushi )

Analysis of sensitivity and cell death pathways mediated by anti-cancer drugs using three-dimensional culture system 2018; 14 (1): 1-12. ( DOI )

Komatsu H, Yagasaki K, Hamamoto Y, Takebayashi T. Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand–Foot Syndrome. Asia Pac J Oncol Nurs.. 2018;

Yasuo Hamamoto, Naoki Sakakibara, Fumio Nagashima, Yuko Kitagawa, Takahiro Higashi. Treatment selection for esophageal cancer: evaluation from a nationwide database Esophagus. 2018; 15 (2): 109-114. ( PubMed, DOI )

Takeuchi M, Suda K, Hamamoto Y, Kato M, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Wada N, Kawakubo H, Takeuchi H, Yahagi N, Kitagawa Y. Technical feasibility and oncological safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointest Endosc.. 2018; 88 (3): 456-465. ( PubMed, DOI )

Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y. Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. Asia Pac J Oncol Nurs.. 2018; 5 (2): 172-177. ( PubMed, DOI )

Matsuda T, Takeuchi H, Sakurai T, Mayanagi S, Booka E, Fujita T, Higuchi H, Taguchi J, Hamamoto Y, Takaishi H, Kawakubo H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett.. 2018; 16 (1): 1348-1356. ( PubMed, DOI )

Jun Hashimoto, Ken Kato, Yoshinori Ito, Takashi Kojima, Tetsuo Akimoto, Hiroyuki Daiko, Yasuo Hamamoto, Hisayuki Matsushita, Susumu Katano, Hiroki Hara, Yoichi Tanaka, Yoshihiro Saito, Kengo Nagashima, Hiroyasu Igaki. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Int J Clin Oncol.. 2018;

Yasuo Hamamoto. Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma. Journal of Thoracic Disease. 2018;

Yasuo Hamamoto. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncol.. 2018;

Kato H, Ono H, Hamamoto Y, Ishikawa H. Interaction between Medical Treatment and Minimally Invasive Surgical Treatment for the Malignancies of the Digestive Tract. Digestion. 2018;

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial 2017.12; 390 (10111): 2461-2471. ( PubMed, DOI )

Curative resectability of gastrointestinal cancer identified from iron deficiency anemia 2017.10; 14 (4): 4301-4304. ( DOI )

Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer 2017.10; 28

Hamamoto Yasuo, Nojima Masanori, Aoki Yu, Suzuki Takeshi, Kawasaki Kenta, Hirata Kenro, Sukawa Yasutaka, Kasuga Akira, Kawakubo Hirofumi, Takeuchi Hiroya, Murakami Koji, Takaishi Hiromasa, Kanai Takanori, Kitagawa Yuko. 局所進行食道扁平上皮癌に対する臨床診断の評価者間不均一性(Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma) Esophagus. 2017.10; 14 (4): 324-332. ( ichushi )

Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report 2017.09; 14 (3): 3697-3700. ( DOI )

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer 2017.06; 143 (6): 1053-1059. ( DOI )

A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer. 2017.05; 35 ( DOI )

ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC)-Efficacy and QOL results. 2017.05; 35 ( DOI )

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial 2017.05; 18 (5): 631-639. ( DOI )

Yasuo Hamamoto. Inter-evaluator Heterogeneity of Clinical Diagnosis for Locally Advanced Esophageal Squamous Cell Carcinoma Esophagus. 2017.03; 14 (4): 1-9. ( PubMed, DOI )

Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy 2017.03; 79 (3): 595-602. ( DOI )

Yokota T, Yasuda T, Kato H, Nozaki I, Sato H, Miyata Y, Kuroki Y, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Kitagawa Y. Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. Int J Clin Oncol.. 2017;

Akira Sawaki, Yasuhide, YamadaKensei YamaguchiTomohiro NishinaToshihiko DoiTaroh, SatohKeisho ChinNarikazu BokuYasushi OmuroYoshito KomatsuYasuo HamamotoWasaburo KoizumiShigehira SajiManish A. ShahEric Van Cutsem, Yoon-Koo Kang, Junko Iwasaki, Hiroshi Kuriki, Wataru Ohtsuka, Atsushi Ohtsu. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm Gastric Cancer. 2017;

堅田 親利, 原 浩樹, 藤井 博文, 伊澤 直樹, 細川 歩, 野村 基雄, 小島 隆嗣, 浜本 康夫, 武藤 学, 田原 信. 食道癌に対する臓器温存を目指した治療戦略　化学療法に基づいた至適な臓器温存戦略(Esophagus preserving strategy for esophageal cancer　An Optimizing Organ Preservation Strategy of Chemotherapy-Based Selection). 日本食道学会学術集会プログラム・抄録集 2024.07.01

松本 繁巳, 門脇 重憲, 町田 望, 仁科 智裕, 砂川 優, 前北 隆雄, 西岡 真理子, 後藤 知之, 浜本 康夫, 安井 久晃, 川邉 里紗, 岡田 昌史, 武藤 学, 室 圭. Cyber Oncologyを活用した進行胃癌治療のreal-world data構築のための実行可能性研究. 日本癌治療学会学術集会抄録集 2023.10.01

對馬 隆浩, 松田 諭, 川久保 博文, 山本 駿, 竹内 裕也, 細川 歩, 門脇 重憲, 渡辺 晃識, 吉井 貴子, 尾形 高士, 陳 勁松, 小谷 大輔, 平田 賢郎, 浜本 康夫, 北川 雄光. 切除可能食道扁平上皮癌に対する術前FLOT療法の第II相試験　初期安全性評価の報告. 日本癌治療学会学術集会抄録集 2023.10.01

千田 彰彦, 浜本 康夫, 野口 智子, 宗 英一郎, 岸本 翔太郎, 堀江 沙良, 斎藤 優樹, 津軽 開, 平田 賢郎, 林 秀幸, 金井 隆典. 高齢消化器がん患者の有害事象発生リスク予測におけるCARG scoreの有用性. 日本癌治療学会学術集会抄録集 2023.10.01

津軽 開, 筋野 智久, 三田 真史, 笹部 潤平, 宮本 健太郎, 原田 洋輔, 鈴木 祥平, 千田 彰彦, 平田 賢郎, 須河 恭敬, 川久保 博文, 加藤 元彦, 浜本 康夫, 金井 隆典. 共生細菌とがん免疫応答　胃癌患者における腸内細菌由来代謝物Dアミノ酸の意義(Commensal bacteria and tumor immunity　Significance of novel microbial metabolites, d-amino acids, in gastric cancer patients). 日本癌学会総会記事 2023.09.01

津軽 開, 浜本 康夫, 山崎 誠, 尾形 高士, 佐藤 真輔, 吉井 貴子, 森田 勝, 佐々木 健, 對馬 隆浩, 北川 雄光. 高齢者・フレイル食道癌患者に対する治療戦略　高齢切除可能胸部食道癌患者における高齢者機能評価の有用性の多施設前向き観察研究. 日本食道学会学術集会プログラム・抄録集 2023.06.01

千田 彰彦, 浜本 康夫, 岸本 翔太郎, 清水 智子, 堀江 沙良, 斎藤 優樹, 下嵜 啓太郎, 津軽 開, 戸ヶ崎 和博, 平田 賢郎, 林 秀幸, 金井 隆典. オンライン診療を用いた緩和ケアの有用性に関する検討. 日本癌治療学会学術集会抄録集 2022.10.01

Hirata Kenro, Hamamoto Yasuo, Shoji Hirokazu, Hara Hiroki, Kondoh Chihiro, Yasui Hisateru, Kajiwara Takeshi, Baba Eishi, Ando Takayuki, Sugimoto Naotoshi, Okano Naohiro, Kawakami Hisato, Katsuya Hiroo, Nagase Michitaka, Moriwaki Toshikazu, Yoshimura Kenichi, Ando Masahiko, Yamazaki Kentaro, Hironaka Shuichi, Muro Kei. 進行胃癌に対する薬物療法の現況　腹膜播種を有する胃癌に対するRAM+PTX併用とRAM+nab-PTX併用に関する第II相比較試験(State of the art of pharmacotherapy for advanced gastric cancer　Phase II trial of RAM combined with PTX vs nab-PTX for gastric cancer with peritoneal dissemination). 日本胃癌学会総会記事 2022.03.01

Yamamoto Shun, Kato Ken, Daiko Hiroyuki, Kojima Takashi, Hara Hiroki, Abe Tetsuya, Tsubosa Yasuhiro, Kawakubo Hirofumi, Fujita Takeo, Fukuda Takashi, Kadowaki Shigenori, Tsushima Takahiro, Hamamoto Yasuo, Nagashima Kengo, Aoki Kazunori, Mizoguchi Yukihiro, Kitano Shigehisa, Yachida Shinichi, Shiba Satoshi, Kitagawa Yuko. 食道がんに対する化学・免疫・放射線療法の可能性　JCOG1804E(FRONTiER)　LAESCCに対する術前CF療法+ニボルマブ投与の実現可能性に関する研究(JCOG1804E(FRONTiER): Feasibility study of nivolumab with neoadjuvant CF for LAESCC). 日本食道学会学術集会プログラム・抄録集 2021.09.01

Abe Kodai, Abe Yuta, Tanaka Masayuki, Hamamoto Yasuo, Kitago Minoru, Yagi Hiroshi, Hasegawa Yasushi, Hori Shutaro, Nakano Yutaka, Kitagawa Yuko. GISTの肝転移に対する肝切除の役割(The role of hepatic resection for liver metastasis from GIST). 日本肝胆膵外科学会・学術集会プログラム・抄録集 2021.06.01

Irino Tomoyuki, Sano Junichi, Matsuda Satoru, Fukuda Kazumasa, Nakamura Rieko, Wada Norihito, Kawakubo Hirofumi, Hirata Kenro, Hamamoto Yasuo, Hirata Yuki, Egawa Tomohisa, Kitagawa Yuko. Conversion Therapy　成績と今後の治療戦略　初期切除不能胃癌に対するconversion surgery　手術の影響(Conversion Therapy-Current outcome and perspecitve Strategies　Conversion surgery for initially-unresectable gastric cancer: the impact of surgery). 日本胃癌学会総会記事 2021.03.01

松田 諭, 川久保 博文, 岡村 明彦, 高橋 慶太, 問端 輔, 竹村 亮, 眞柳 修平, 平田 賢郎, 入野 誠之, 浜本 康夫, 竹内 裕也, 渡邊 雅之, 北川 雄光. 切除可能食道癌に対する術前化学療法の奏効と再発形式の検討　手術回避戦略の可能性. 日本癌治療学会学術集会抄録集 2020.10.01

Kayashima Atsuto, Sujino Tomohisa, Shimozaki Keitaro, Mutaguchi Makoto, Hirata Kenro, Sukawa Yasutaka, Takabayashi Kaoru, Hayashi Yuichiro, Hamamoto Yasuo, Hosoe Naoki, Naganuma Makoto, Ogata Haruhiko, Kanai Takanori. ニボルマブ開始後に増悪し特異な内視鏡的所見を呈した潰瘍性結腸炎の1症例(A case of ulcerative colitis exacerbated after starting nivolumab and followed a unique endoscopic feature). Gastroenterological Endoscopy 2020.08.01

高橋 雅信, 加藤 健, 岡田 守人, 陳 勁松, 門脇 重憲, 浜本 康夫, 土岐 祐一郎, 久保田 祐太郎, 川上 尚人, 尾形 高士, 原 浩樹, 武藤 学, 中島 雄一郎, 北川 雄光. 新規臨床試験最新情報　食道がんに対するニボルマブの開発状況について. 日本癌治療学会学術集会抄録集 2019.10.01

鈴木 健, 春日 章良, 野島 正寛, 岸本 翔太郎, 斎藤 優樹, 津軽 開, 下嵜 啓太郎, 戸ヶ崎 和博, 川崎 健太, 平田 賢郎, 林 秀幸, 須河 恭敬, 浜本 康夫, 高石 官均, 金井 隆典. 癌種横断的な免疫チェックポイント阻害剤の有効性におけるネットワークメタ解析. 日本癌治療学会学術集会抄録集 2019.10.01

浜本 康夫, 山崎 誠, 渡邊 雅之, 安部 哲也, 坪佐 恭宏, 浜井 洋一, 村上 健太郎, 番場 竹生, 吉井 貴子, 津田 政広, 矢野 雅彦, 渡邉 昌也, 上野 正紀, 三梨 桂子, 北川 雄光. 高齢食道扁平上皮がんに対する治療選択. 日本癌治療学会学術集会抄録集 2019.10.01

浜本 康夫. Systemic Chemotherapy for metastatic pancreatic cancer. European Cancer Congress, Amsterdam 2017 2017.01.01